Kamil Paruch

Dr. Kamil Paruch


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PMPaula Martin Moyano
Paula Martin Moyano
VNVáclav Němec
Václav Němec
KPKamil Paruch
Kamil Paruch
Protein kinases represent a very pharmacologically attractive class of targets; however, some members of the family still remain rather unexplored. The biology and therapeutic potential of cdc-like kinases (CLKs) have been explored mainly over the last decade and the first CLK inhibitor, compound SM08502, entered clinical trials only recently. This review summarizes the biological roles and therapeutic potential of CLKs and their heretofore published small-molecule inhibitors, with a focus on the compounds’ potential to be utilized as quality chemical biology probes.

1 January 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MLMarc Labroli
Marc Labroli
KPKamil Paruch
Kamil Paruch
MDMichael P. Dwyer
Michael P. Dwyer
CACarmen Alvarez
Carmen Alvarez
KKKartik Keertikar
Kartik Keertikar
TGTimothy J. Guzi
Timothy J. Guzi

20 December 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
VNVáclav Němec
Václav Němec
MHMichaela Hylsová
Michaela Hylsová
LMLukáš Maier
Lukáš Maier
JFJana Flegel
Jana Flegel
SSSonja Sievers
Sonja Sievers
KPKamil Paruch
Kamil Paruch

1 January 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MHMichaela Hylsová
Michaela Hylsová
BCBenoit Carbain
Benoit Carbain
JFJindrich Fanfrlik
Jindrich Fanfrlik
LMLenka Musilová
Lenka Musilová
SHSusanta Haldar
Susanta Haldar
MLMartin Lepšík
Martin Lepšík

1 April 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VNVáclav Němec
Václav Němec
LMLukáš Maier
Lukáš Maier
BBBenedict-Tilman Berger
Benedict-Tilman Berger
Apirat ChaikuadApirat Chaikuad
Apirat Chaikuad
SDStanislav Drápela
Stanislav Drápela
KPKamil Paruch
Kamil Paruch

11 April 2019 in Haematologica
Verified
Journal Article
Open access
PDF file
MBMiroslav Boudny
Miroslav Boudny
JZJana Zemanova
Jana Zemanova
PKPrashant Khirsariya
Prashant Khirsariya
MBMarek Borsky
Marek Borsky
JVJan Verner
Jan Verner
MTMartin Trbusek
Martin Trbusek
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is therefore of critical importance. Herein, we detail anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G2/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2Rγnull) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.